The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
Open accessAbstract
Objective : To estimate by how much and how quickly a given reduction in serum cholesterol concentration will reduce the risk of ischaemic heart disease. Design : Data on the incidence of ischaemic heart disease and serum cholesterol concentration were analysed from 10 prospective (cohort) studies, three international studies in different communities, and 28 randomised controlled trials (with mortality data analysed according to allocated treatment to ensure the avoidance of bias). Main outcome measure - Decrease in incidence of ischaemic heart disease or mortality for a 0.6 mmol/l (about 10%) decrease in serum cholesterol concentration. Results : For men results from the cohort studies showed that a decrease of serum cholesterol concentration of 0.6 mmol/l (about 10%) was associated with a decrease in incidence of ischaemic heart disease of 54% at age 40 years, 39% at age 50, 27% at 60, 20% at 70, and 19% at 80. The combined estimate from the three international studies (for ages 55-64 years) was 38% (95% confidence interval 33% to 42%), somewhat greater than the cohort study estimate of 27%. The reductions in incidence of ischaemic heart disease in the randomised trials (for ages 55-64 years) were 7% (0 to 14%) in the first two years, 22% (15% to 28%) from 2.1-5 years, and 25% (15% to 35%) after five years, the last estimate being lose to the estimate of 27% for the long term reduction from the cohort studies. The data for women are limited but indicate a similar effect. Conclusions - The results from the cohort studies, international comparisons, and clinical trials are remarkably consistent. The cohort studies, based on half a million men and 18 000 ischaemic heart disease events, estimate that a long term reduction in serum cholesterol concentration of 0.6 mmol/l (10%), which can be achieved by moderate dietary change,lowers the risk of ischaemic heart disease by 50% at age 40, falling to 20% at age 70. The randomised trials, based on 45 000 men and 4000 ischaemic heart disease events show that the full effect of the reduction in risk is achieved by five years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Burr, M. L., Gilbert, J. F., Holliday, R. M., Elwood, P. C., Fehily, A. M., Rogers, S., Sweetnam, P. M., & Deadman, N. M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90828-3 · Cited by 2,610
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Blankenhorn, D. H. (1987) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1987.03390230069027 · Cited by 1,655
Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-5-786_2 · Cited by 1,418
Martindale. The Extra Pharmacopoeia.
(1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-5-687_2 · Cited by 1,111
Cited by
Items 101–146 of 146
Byington, R. P., Jukema, J. W., Salonen, J. T., Pitt, B., Bruschke, A. V., Hoen, H., Furberg, C. D., & Mancini, G. B. J. (1995) · Circulation · doi:10.1161/01.cir.92.9.2419 · Cited by 283
Cicero, A. F. G., Colletti, A., Bajraktari, G., Descamps, O., Djuric, D. M., Ezhov, M., Fras, Z., Katsiki, N., Langlois, M., Latkovskis, G., et al. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.69326 · Cited by 281
“5 mmol/l) are associated with a low risk for CHD and are considered optimal in the absence of CVD or other risk factors [17].”
BackgroundDistribution of Major Health Risks: Findings from the Global Burden of Disease Study
Rodgers, A., Ezzati, M., Vander Hoorn, S., Lopez, A. D., Lin, R.-B., Murray, C. J. L., & Group Comparative Risk Assessment Collaborating (2004) · PLoS Medicine · doi:10.1371/journal.pmed.0010027 · Cited by 280
Magnus, P., & Beaglehole, R. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.22.2657 · Cited by 277
O'Donovan, G., Owen, A., Bird, S. R., Kearney, E. M., Nevill, A. M., Jones, D. W., & Woolf-May, K. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01310.2004 · Cited by 276
Cholesterol Reduction Yields Clinical Benefit: A New Look at Old Data
Gould, A. L., Rossouw, J. E., Santanello, N. C., Heyse, J. F., & Furberg, C. D. (1995) · Circulation · doi:10.1161/01.cir.91.8.2274 · Cited by 272
Tang, J. L., Armitage, J. M., Lancaster, T., Silagy, C. A., Fowler, G. H., Neil, H. A. W., Smith, G. D., & Ebrahim, S. (1998) · BMJ · doi:10.1136/bmj.316.7139.1213 · Cited by 275
Pedersen, T. R., Wilhelmsen, L., Færgeman, O., Strandberg, T. E., Thorgeirsson, G., Troedsson, L., Kristianson, J., Berg, K., Cook, T. J., Haghfelt, T., et al. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)00910-3 · Cited by 274
Vincent-Baudry, S., Defoort, C., Gerber, M., Bernard, M.-C., Verger, P., Helal, O., Portugal, H., Planells, R., Grolier, P., Amiot-Carlin, M.-J., et al. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/82.5.964 · Cited by 274
Telehealth interventions for the secondary prevention of coronary heart disease: a systematic review
Neubeck, L., Redfern, J. U., Fernandez, R., Briffa, T., Bauman, A., & Freedman, S. B. (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e32832a4e7a · Cited by 268
Risk factor thresholds: their existence under scrutiny
Law, M. R., & Wald, N. J. (2002) · BMJ · doi:10.1136/bmj.324.7353.1570 · Cited by 268
Self-citationExercise Dose in Clinical Practice
Wasfy, M. M., & Baggish, A. L. (2016) · Circulation · doi:10.1161/circulationaha.116.018093 · Cited by 268
Factores de riesgo cardiovascular. Perspectivas derivadas del Framingham Heart Study
O’Donnell, C. J., & Elosua, R. (2008) · Revista Española de Cardiología · doi:10.1157/13116658 · Cited by 266
Cardiovascular Risk Factors. Insights From Framingham Heart Study
O'Donnell, C. J., & Elosua, R. (2008) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(08)60118-8 · Cited by 265
Weggemans, R. M., & Trautwein, E. A. (2003) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1601628 · Cited by 265
Simes, R. J., Marschner, I. C., Hunt, D., Colquhoun, D., Sullivan, D., Stewart, R. A. H., Hague, W., Keech, A., Thompson, P., White, H., et al. (2002) · Circulation · doi:10.1161/hc1002.105136 · Cited by 254
MacMahon, S., Sharpe, N., Gamble, G., Hart, H., Scott, J., Simes, J., & White, H. (1998) · Circulation · doi:10.1161/01.cir.97.18.1784 · Cited by 254
Capewell, S., Beaglehole, R., Seddon, M., & McMurray, J. (2000) · Circulation · doi:10.1161/01.cir.102.13.1511 · Cited by 253
Dodin, S., Lemay, A., Jacques, H., Légaré, F., Forest, J.-C., & Mâsse, B. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1148 · Cited by 244
Kotseva, K., Wood, D., De Backer, G., De Bacquer, D., Pyörälä, K., Reiner, Ž., Keil, U., & EUROASPIRE Study Group (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283383f30 · Cited by 238
Reduction in saturated fat intake for cardiovascular disease
Hooper, L., Martin, N., Jimoh, O. F., Kirk, C., Foster, E., & Abdelhamid, A. S. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011737.pub2 · Cited by 228
Effect of garlic on serum lipids: an updated meta-analysis
Ried, K., Toben, C., & Fakler, P. (2013) · Nutrition Reviews · doi:10.1111/nure.12012 · Cited by 203
Capewell, S., Ford, E. S., Croft, J. B., Critchley, J. A., Greenlund, K. J., & Labarthe, D. R. (2010) · Bulletin of the World Health Organization · doi:10.2471/blt.08.057885 · Cited by 200
Danaei, G., Rimm, E. B., Oza, S., Kulkarni, S. C., Murray, C. J. L., & Ezzati, M. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000248 · Cited by 191
“Most of the benefits nonetheless seem to occur within about 5 y for cardiovascular risk factors [44]; even for the effects of smoking on cancers and chronic respiratory diseases, which have longer periods of risk reversibility, 75% or more of the benefits of cessation occur by about 15 y [45].”
BackgroundMeta-analysis: Unresolved issues and future developments
Smith, G. D., & Egger, M. (1998) · BMJ · doi:10.1136/bmj.316.7126.221 · Cited by 175
Nnoaham, K. E., Sacks, G., Rayner, M., Mytton, O., & Gray, A. (2009) · International Journal of Epidemiology · doi:10.1093/ije/dyp214 · Cited by 169
Trends in the prevalence, awareness, treatment and control of hypertension: the WHO MONICA Project
Antikainen, R. L., Moltchanov, V. A., Chukwuma, C., Kuulasmaa, K. A., Marques-Vidal, P. M., Sans, S., Wilhelmsen, L., & Tuomilehto, J. O. (2006) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/00149831-200602000-00004 · Cited by 132
Law, M. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.5.1291s · Cited by 115
Self-citationOrlistat Inhibits Dietary Cholesterol Absorption
Mittendorfer, B., Ostlund, R. E., Patterson, B. W., & Klein, S. (2001) · Obesity Research · doi:10.1038/oby.2001.79 · Cited by 114
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus
Norris, S. L., Zhang, X., Avenell, A., Gregg, E., Schmid, C. H., & Lau, J. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004096.pub2 · Cited by 113
Which interventions offer best value for money in primary prevention of cardiovascular disease
Cobiac, L. J., Magnus, A., Lim, S., Barendregt, J. J., Carter, R., & Vos, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041842 · Cited by 97
“80% reduction in relative risk of stroke [13,50,51].”
BackgroundMcAninch, E. A., Rajan, K. B., Miller, C. H., & Bianco, A. C. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01361 · Cited by 94
Explaining the decline in coronary heart disease mortality in Turkey between 1995 and 2008
Unal, B., Sözmen, K., Arık, H., Gerçeklioğlu, G., Altun, D. U., Şimşek, H., Doganay, S., Demiral, Y., Aslan, Ö., Bennett, K., et al. (2013) · BMC Public Health · doi:10.1186/1471-2458-13-1135 · Cited by 82
Lactation and cardiovascular risk factors in mothers in a population-based study: the HUNT-study
Natland, S. T., Nilsen, T. I. L., Midthjell, K., Andersen, L. F., & Forsmo, S. (2012) · International Breastfeeding Journal · doi:10.1186/1746-4358-7-8 · Cited by 80
Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis
Genser, B., & März, W. (2006) · Clinical Research in Cardiology · doi:10.1007/s00392-006-0403-x · Cited by 68
“In almost all prospective population studies, the relationship between cholesterol or LDL-C and coronary events has been well described using exponential functions [9, 13, 14, 26].”
BackgroundCholesterol Reduction and Clinical Benefit: Are There Limits to Our Expectations?
Fager, G., & Wiklund, O. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.12.3527 · Cited by 62
Kim, H.-Y., & Park, K.-Y. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.05.052 · Cited by 54
Hunninghake, D. B., Maki, K. C., Kwiterovich, P. O., Davidson, M. H., Dicklin, M. R., & Kafonek, S. D. (2000) · Journal of the American College of Nutrition · doi:10.1080/07315724.2000.10718931 · Cited by 52
McIntyre, R. S., Alsuwaidan, M., Goldstein, B. I., Taylor, V. H., Schaffer, A., Beaulieu, S., & Kemp, D. E. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400108 · Cited by 45
Wood, G., Taylor, E., Ng, V., Murrell, A., Patil, A., van der Touw, T., Sigal, R., Wolden, M., & Smart, N. (2022) · British Journal of Sports Medicine · doi:10.1136/bjsports-2021-103999 · Cited by 45
Implications of apolipoprotein E genotype on inflammation and vitamin E status
Huebbe, P., Lodge, J. K., & Rimbach, G. (2010) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200900398 · Cited by 43
McAlister, F. A., Taylor, L., Teo, K. K., Tsuyuki, R. T., Ackman, M. L., Yim, R., Montague, T. J., & The Clinical Quality Improvement Network (CQIN) Investigators (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb03837.x · Cited by 39
Toh, D. W. K., Koh, E. S., & Kim, J. E. (2020) · Nutrition Reviews · doi:10.1093/nutrit/nuz104 · Cited by 33
Fuentes, M. C., Lajo, T., Carrión, J. M., & Cuñé, J. (2016) · Mediterranean Journal of Nutrition and Metabolism · doi:10.3233/mnm-160065 · Cited by 31
Unal, B., Critchley, J., & Capewell, S. (2003) · Tobacco Induced Diseases · doi:10.1186/1617-9625-1-3-185 · Cited by 8
Metadata
- Authors
- Law, M. R., Wald, N. J., & Thompson, S. G.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1994-02-05
- Volume
- 308
- Issue
- 6925
- Pages
- 367-372
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2132931461
- Cited by
- 1,210
- References
- 70
- FWCI
- 79.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.